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OBJECTIVES: To assess symptoms reported by IBS-C patients through exploratory
open-ended questions in two phase 3 clinical trials.METHODS: Prior to answering
a daily symptom diary, patients were asked to list bothersome symptoms of IBS-C
in an open-ended manner at the pre-treatment visit. At the randomization visit,
patientswere asked to list any additional bothersome symptoms of IBS-C thatwere
not assessed during the prior two weeks. The data at both time points for random-
ized patients were analyzed using ATLAS.ti. Codes were developed using patients’
verbatimwords. Frequency counts of symptomswere tabulated. Resultswere com-
paredwith symptoms reported from four focus groupswith IBS-C patients (n 32).
RESULTS: Across trials, 1496/1610 (92.9%) and 603/1610 (37.5%) patients provided
responses at the pre-treatment and randomization visit, respectively. The ten
bothersome symptoms of IBS-C listed by patients most frequently at the pre-treat-
ment visit were: bloating (76.1%), cramping (39.0%), gas (31.6%), constipation
(29.1%), abdominal pain (24.8%), pain (general) (21.1%), fullness (20.0%), straining
(14.4%), pain (stomach) (13.4%), and UBM (13.1%). Out of the patients reporting
additional symptoms at randomization, the fivemost frequently listed bothersome
symptoms were: gas (23.1%), bloating (14.1%), cramping (12.9%), fullness (11.6%),
and nausea (11.6%). Only two of these symptoms identified at the randomization
visit were not assessed during the trial: gas and nausea. The symptoms most fre-
quently reported by patients in the trial were reported during the focus groups.
CONCLUSIONS: This method of data collection provided insight on IBS-C patient
perspective. Adult IBS-C patients experiencemany bothersome symptoms, includ-
ing both abdominal and bowel symptoms. The results from this analysis confirm
the comprehensiveness of four focus groups conducted with IBS-C patients and
provides evidence that across different IBS-C patient groups the type of abdominal
and bowel symptoms reported by patients is consistent.
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OBJECTIVES: Ulcerative colitis (UC) is a chronic inflammatory disease of the large
intestine and rectum. Symptoms such as abdominal pain, diarrhea, and the per-
sistent urge to defecate can impair UC patients’ physical and socio-psychological
well-being. This study examined themagnitude of this impairment, and the degree
towhich treatment improved health-related quality of life (HRQL), ofmild-to-mod-
erate UC patients relative to a US general population sample. METHODS: Short-
Form (SF)-12v2 baseline and endpoint scores were collected from a multicenter,
open-label study in which patients with active mild-to-moderate UC received
multi-matrix (MMX) mesalamine 2.4–4.8g/day QD for 8 weeks. Patients were com-
pared with a 2009 US general population sample derived from an Internet-based
survey administered to a representative national sample of adults. The normative
sample was matched to the age and sex of the patient sample using least squares
regression. Analysis of variance models tested for significant differences between
UC patients’ mean scores and normative sample’s estimated scores at each time.
Group comparisons onphysical andmental summary scores (PCS andMCS, respec-
tively) relative to established minimally significant differences (MID) of 3 points
identified clinically meaningful group differences. RESULTS: Baseline SF-12v2
scores for UC patients were significantly below thematched general population on
7 of 8 subscales (all P0.01 except formental health, P0.05) and on both summary
measures (PCS: 45.4 vs. 50.4, P0.001; MCS: 47.3 vs. 49.4, P0.05). Sample differ-
ences for PCS scores but not MCS scores exceeded the establishedMID. At 8 weeks,
SF-12v2 scores of the treated UC patients were either statistically equivalent to or
exceeded norm scores. CONCLUSIONS: Active UC negatively impacted almost all
dimensions of HRQL; the burden in physical health dimension was larger than the
burden in mental health. Eight weeks of daily MMX mesalamine treatment im-
proved patients to “normal” levels of functioning and well-being.
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OBJECTIVES: To understand the correspondence across measures of patient-re-
ported outcomes (PRO) in quiescent ulcerative colitis (UC) patients, we examined
the responsiveness to treatment, sensitivity to disease activity, and inter-associa-
tions amongmeasures of generic and disease-specific health-related quality of life
(HRQL) and work-related outcomes. METHODS: Patients with UC in quiescence
(defined by a lack of rectal bleeding and normal frequency of defecation) received
2.4 g/day multi-matrix (MMX) mesalamine daily for 12 months in a multicenter,
prospective, open-label study. PROs were administered at baseline, 6 months, and
12 months. The Short Form (SF)-12v2 measured generic HRQL, the shortened In-
flammatory Bowel Disease Questionnaire (SIBDQ) measured IBD-specific HRQL,
and the Work Productivity and Activity Impairment Questionnaire for UC (WPAI:
UC) measured absenteeism and work productivity. Repeated-measures ANOVAs
examined changes in scores over time. Associations among instruments were as-
sessed by inter-subscale correlations. Sensitivity to disease activity was assessed
using ANCOVA models to compare PRO endpoint scores between recurrent and
non-recurrent patients (recurrence is defined as 4 or more bowel movements/day
above normal, and evidence of urgency, abdominal pain or rectal bleeding). Data
were collected at baseline, Month 6, andMonth 12/early withdrawal. RESULTS: 198
patients were enrolled at baseline. In quiescent patients, no changes in any PRO
instrument subscale occurred over time (all p0.10). Overall, small to moderate
inter-subscale correlationswere found across all instruments: average correlations
were 0.37 between SF-12v2 and SIBDQ subscales, 0.33 between SF-12v2 and
WPAI:UC subscales, and 0.43 between SIBDQ and WPAI:UC subscales. Most sub-
scales demonstrated statistically worse outcomes for patients with recurrent UC.
CONCLUSIONS: In quiescent UC patients, instruments measuring different out-
comes associated with UC showed stability during 12-month maintenance treat-
ment withMMXmesalamine. The strength of inter-scale correlations and the find-
ing of similar sensitivity to clinical outcomes indicate convergent validity among
these instruments within this patient population.
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OBJECTIVES: ADVANCE and ILLUMINATE, phase 3 studies, evaluated efficacy and
safety of telaprevir (T)/peginterferon alfa-2a/ribavirin (PR) for genotype 1 HCV
treatment-naïve patients. ADVANCE patients were randomized to 8 or 12 weeks of
T/placebo plus PR (24 or 48 weeks) or PR (48 weeks). ILLUMINATE patients received
T plus PR for 12 weeks; those with extended rapid virologic response (eRVR) were
randomized to 24- or 48-week total treatment. We report on the patient self-re-
ported impact of telaprevir-based regimens on work productivity.METHODS: The
five-item Work Productivity Questionnaire (WPQ) was administered to patients
(N932) at day 1, and weeks 4, 12, 24, 36, 48 and 72 (assessed previous 4 weeks).
WPQ responses were tabulated at each timepoint by treatment group using de-
scriptive statistics.RESULTS:At baseline, daysmissed fromwork (mean, SD) due to
HCV or its treatment ranged from 0.8 (3.6) to 1.1 (4.4) days across treatment groups
(ADVANCE), and from 0.6 (3.1) to 0.7 (3.3) (eRVR groups, ILLUMINATE) and in-
creased 4-5 fold by week 12 in ADVANCE and ILLUMINATE. Compared to baseline,
more patients reportedworking shorter hours and being less productive byweek 12
in ADVANCE and in ILLUMINATE eRVR groups. At week 48, days missed from
work approached baseline levels in telaprevir treatment groups (1.1 [4.9] T12PR; 1.0
[4.7] T8PR) but not in PR (1.9 [6.3]); in ILLUMINATE corresponding values were 0.1
(0.5) in T12PR24 and 0.8 (2.3) in T12PR48. After week 12, other work productivity
measures improved earlier in telaprevir-based groups versus PR (ADVANCE), and
in T12PR24 versus T12PR48 in ILLUMINATE (eRVR). CONCLUSIONS:Among geno-
type 1 HCV treatment-naïve patients, work productivity decreased during the first
twelve weeks of therapy in all treatment arms. Work productivity, however, re-
turned to pre-treatment levels earlier in patients who received telaprevir-based
regimens compared with PR and in those patients who received shorter treatment
duration.
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OBJECTIVES: Irritable bowel syndrome (IBS) is a relapsing, chronic functional gas-
trointestinal disorder with continuous nuisance bowel symptoms leading to long-
term disturbances on quality of life (QoL). Various conventional and innovative
gastrointestinal drugs are available for the symptomatic control of IBS. However, it
is uneasy to justify cost-effectiveness of IBS treatments due to the unspecific symp-
toms, a disparity of QoL measurements and a lack of clear association between
functioning and QoL. This preliminary used a qualitative approach to explore the
impacts of IBS on patients and explore underlying attributes to QoL. METHODS:
Semi-structure interviews were conducted at amedical center in southern Taiwan
from July 2010 to December 2010. Outpatients with defined diagnosis of IBS and
receivingmedical treatmentwere invited to participate, and a topic guidewas used
to ensure systematic coverage of attributes related to QoL. The interviews were
audiotaped and transcribed verbatim for framework analysis. RESULTS: The most
disturbing symptoms for 29 participantswere recurrent abdominal pain or discom-
fort, which affect the efficiency of work or study. In addition, the frequent bowel
movements reduce patient’s willingness to participate in social activities and jeop-
ardize their interpersonal relationship. Moreover, repeated inspections and medi-
cal visits during follow-ups also raise patients’ further concerns and worries on
health. Unsatisfied symptoms control was commonly stated by participants and
alternative managements such as homeopathic remedies, traditional Chinese
medicines, sports, and diet modifications were tried and considered being ineffec-
tive. Some participants with uncontrolled symptoms acknowledged their failure in
adhering to medical treatment due to the concerns of adverse drug reactions.
CONCLUSIONS: For patients with potentially moderate to severe IBS and consis-
tent medical treatments, the functional impairment was still tolerable yet intan-
gible (anxiety, worries) and social stress may have greater impacts on QoL. There-
fore, a capability approach may work better than the utility and functioning QoL
measure.
A184 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
